SCHEMBL5108941

SCHEMBL5108941

CC(C)(C)OC(=O)N1CCN(CCOc2ccc(NC(=O)COc3ccc(C(F)(F)F)cc3Cl)cc2Cl)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.56
MAPT P10636 4/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 2/20 0.44
HTT P42858 2/20 0.44
GPR119 Q8TDV5 1/20 0.44
EPHX2 P34913 2/20 0.43
HTR2A P28223 4/20 0.43
HTR2C P28335 4/20 0.43
TSHR P16473 2/20 0.43
HSD17B10 Q99714 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008808 0.89 RXFP1 (0.44) RXFP1MAPTMEN1KMT2ALMNA
SCHEMBL4006678 0.87 ACHE (0.55) RXFP1MAPTKMT2ALMNASMN1; SMN2
SCHEMBL4008085 0.86 ACHE (0.56) RXFP1MAPTHPGDMAPK1HTR2A
SCHEMBL4004890 0.84 MCHR1 (0.51) RXFP1MAPTEPHX2HTR2AHTR2C
SCHEMBL5114417 0.84 NR3C1 (0.41) RXFP1MAPTMEN1KMT2ALMNA
SCHEMBL4006855 0.84 HTR2A (0.47) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4010472 0.83 ACHE (0.46) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4008233 0.83 MRGPRX4 (0.51) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL14209953 0.83 SCN9A (0.44) RXFP1MAPTMEN1KMT2ALMNA
SCHEMBL4010360 0.82 SMN1; SMN2 (0.46) MAPTMEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351719-B2 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-04-01 US disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds MCHR2, MCHR1, NPY1R RXFP1 42/4885MAPT 4346/4885MEN1 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.